BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

Phase 3

Terminated

Conditions: Urinary Bladder Neoplasms

Interventions: Drug: nivolumab
Other: Placebo
Biological: Bacillus Calmette-Guérin (BCG)

First Posted Date: 2019-11-04

Last Posted Date: 2024-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 13

Registration Number: NCT04149574

Locations: 🇦🇺
Local Institution - 0002, Sydney, New South Wales, Australia
🇦🇷
Local Institution - 0088, Capital Federal, Buenos Aires, Argentina
🇯🇵
Local Institution - 0150, Shinjuku-Ku, Tokyo, Japan

and more 78 locations

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: nivolumab

First Posted Date: 2019-10-31

Last Posted Date: 2022-01-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT04146324

Locations: 🇦🇺
Local Institution, Malvern, Victoria, Australia

A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US

Completed

Conditions: Venous Thromboembolism (VTE)

First Posted Date: 2019-10-28

Last Posted Date: 2019-10-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 28000

Registration Number: NCT04141228

Locations: 🇺🇸
Local Institution, Flemington, New Jersey, United States

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Drug: Nab-paclitaxel

First Posted Date: 2019-10-21

Last Posted Date: 2022-12-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT04132817

Locations: 🇺🇸
Local Institution, Dallas, Texas, United States
🇺🇸
Local Institution - 0003, Sacramento, California, United States
🇺🇸
Local Institution - 0009, Aurora, Colorado, United States

and more 3 locations

A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke

Phase 4

Completed

Conditions: Atrial Fibrillation
Atrial Flutter

Interventions: Other: Zio®XT Monitor

First Posted Date: 2019-10-15

Last Posted Date: 2023-07-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 11931

Registration Number: NCT04126486

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Dayton Clinical Research, Dayton, Ohio, United States
🇺🇸
Local Institution - 0051, Boston, Massachusetts, United States

and more 165 locations

A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: rosuvastatin
Drug: BMS-963272

First Posted Date: 2019-10-11

Last Posted Date: 2020-03-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 28

Registration Number: NCT04124003

Locations: 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults

Phase 1

Completed

Conditions: Obese But Otherwise Healthy Participants

Interventions: Drug: BMS-963272
Drug: Placebo

First Posted Date: 2019-10-04

Last Posted Date: 2020-05-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT04116632

Locations: 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: diflunisal

First Posted Date: 2019-10-03

Last Posted Date: 2020-08-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 48

Registration Number: NCT04113668

Locations: 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: relatlimab
Drug: nivolumab
Drug: rHuPH20

First Posted Date: 2019-10-02

Last Posted Date: 2023-04-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT04112498

Locations: 🇺🇸
Local Institution - 0001, Hackensack, New Jersey, United States

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Biological: nivolumab
Drug: paclitaxel (PTX)
Other: nivolumab placebo
Drug: anthracycline
Drug: cyclophosphamide
Drug: Endocrine Therapy
Procedure: Surgery

First Posted Date: 2019-09-30

Last Posted Date: 2024-03-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 521

Registration Number: NCT04109066

Locations: 🇧🇪
Local Institution - 0031, Liege, Belgium
🇩🇪
Local Institution - 0157, Velbert, Germany
🇳🇱
Local Institution - 0177, Breda, Netherlands

and more 229 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy